Evidence map›Paper›PMID 34765751›Full record

ArticleTechnical innovations & patient support in radiation oncology2021

Thyroid-optimized and thyroid-sparing radiotherapy in oral cavity and oropharyngeal carcinoma: A dosimetric study.

Anna K Wu, Nicholas J Damico, Erin Healy, Michael Z Kharouta, Ghazal Khandel, Alok Deshane, Jennifer Sipos, Jacob Eckstein, Wesley Zoller, Ashlee Ewing and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technical innovations & patient support in radiation oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Anna K WuCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Nicholas J DamicoDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Erin HealyDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Michael Z KharoutaDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Ghazal KhandelDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
Alok DeshaneCase Western Reserve University School of Medicine, Cleveland, OH, USA.
Jennifer SiposDepartment of Endocrinology, Ohio State University, Columbus, OH, USA.
Jacob EcksteinDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Wesley ZollerDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Ashlee EwingDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Stella LingDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Jessica WobbDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Darrion MitchellDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
John GreculaDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Sachin JhawarDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Eric MillerDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Mauricio GamezDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Virginia DiavolitsisDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Dukagjin BlakajDepartment of Radiation Oncology, Ohio State University, Columbus, OH, USA.
Aashish D BhattDepartment of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRadiation-induced hypothyroidism is a common toxicity of head and neck radiation. Our re-planning study aimed to reduce thyroid dose while maintaining target coverage with IMRT.

methodsWe retrospectively identified patients with oral-cavity (n = 5) and oropharyngeal cancer (n = 5). Treatment plans were re-optimized with 45 Gy thyroid mean dose constraint, then we cropped the thyroid out of PTVs and further reduced thyroid dose. Target coverage was delivering 100% dose to ≥ 93% of PTV and 95% of dose to > 99% of PTV.

resultsOriginally, average mean dose to thyroid was 5580 cGy. In model I, this dropped to 4325 cGy (p < 0.0001). In model II, average mean dose was reduced to 3154 cGy (p < 0.0001). For PTV low and PTV int, all had acceptable target coverage.

conclusionIn patients with oral-cavity and oropharyngeal cancers, mean dose could be significantly reduced using a thyroid-optimized or thyroid-sparing IMRT technique with adequate coverage.

Indexed as

HypothyroidismIntensity-modulated radiotherapyRadiation toxicityThyroid-optimizedThyroid-sparing

Identifiers

PMID34765751
PMCPMC8571516

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.